firmagon
ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
firmagon 120 mg
fering gmbh - germania - degarelix - pulb.+solv. pt. sol. inj. - 120 mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite
firmagon 80 mg
fering gmbh - germania - degarelix - pulb.+solv. pt. sol. inj. - 80 mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite
Кемира pro git sf
srl Сумма Агро Сервис - acizi organici, calciu - suine
barrier ultra
Îp barieră-profi, ucraina - imidacloprid, - soluţie pentru aplicarea cutanată - câini
insectal picături
zao npf ekoprom, rusia - fipronil, - soluţie spot on - cîini, pisici
zgardă inspector
zao npf ecoprom, rusia - fipronil, - zgardă antiparazitară - câini, pisici
alben 360 mg, comprimate
sc vermodjesrl, moldova - albendazol - comprimate - овечий
alben 400mg, capsule
sc vermodjesrl, moldova - albendazol - capsule - овечий
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostate neoplasme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.